Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Debled

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
ESMO Open|May 13, 2021
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life databaseM Carausu, M Carton, A Darlix, et al.
Breast Cancer Research and Treatment|January 5, 2022
Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohortM Bringuier, M Carton, C Levy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2016
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyS Delaloge, D Pérol, C Courtinard, et al.
ESMO Open|April 25, 2021
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortT Grinda, A Antoine, W Jacot, et al.
ESMO Open|November 26, 2025
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohortF Cherifi, L Cabel, C Bousrih, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
ESMO Open|May 13, 2021
Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life databaseM Carausu, M Carton, A Darlix, et al.
Breast Cancer Research and Treatment|January 5, 2022
Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohortM Bringuier, M Carton, C Levy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2016
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyS Delaloge, D Pérol, C Courtinard, et al.
ESMO Open|April 25, 2021
Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortT Grinda, A Antoine, W Jacot, et al.
ESMO Open|November 26, 2025
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohortF Cherifi, L Cabel, C Bousrih, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Pageof 5